Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P00352

UPID:
AL1A1_HUMAN

ALTERNATIVE NAMES:
3-deoxyglucosone dehydrogenase; ALDH-E1; ALHDII; Aldehyde dehydrogenase family 1 member A1; Aldehyde dehydrogenase, cytosolic; Retinal dehydrogenase 1

ALTERNATIVE UPACC:
P00352; O00768; Q5SYR1

BACKGROUND:
Aldehyde dehydrogenase 1A1, also referred to as ALDH-E1 and Aldehyde dehydrogenase, cytosolic, is a key enzyme in the oxidation of aldehydes to carboxylic acids. It functions downstream of retinol dehydrogenases, facilitating the conversion of retinaldehyde to retinoic acid, a critical step in the metabolic pathway from retinol to retinoic acid. This enzyme ensures the regulation of retinol and retinoic acid levels, vital molecules whose imbalance can lead to cytotoxicity and teratogenicity. Additionally, it plays a role in the degradation of toxic aldehydes formed during lipid peroxidation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Aldehyde dehydrogenase 1A1's function offers promising avenues for therapeutic intervention. Given its crucial role in aldehyde detoxification and retinol metabolism, targeting this enzyme could lead to novel treatments for conditions arising from oxidative damage and abnormal vitamin A metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.